ArticleBreast cancer research and treatment2026
Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe risk of ipsilateral breast tumor recurrence (IBTR) and the prognostic outcomes of breast-conserving surgery (BCS) for germline BRCA1/2 pathogenic variant carriers (BRCA+) remain controversial. This study aimed to investigate the differences in the incidence of IBTR and prognosis between BRCA + and noncarriers (BRCA-) after BCS.
methodsA retrospective chart review was performed in patients with stage 0-III breast cancer who underwent genetic testing for germline BRCA1/2 and BCS between 1996 and 2020. We compared the incidence of IBTR and the characteristics and prognostic outcomes of IBTR, including overall survival (OS), breast cancer-specific survival (BCSS), and distant recurrence-free survival (DRFS), between BRCA + and BRCA- after BCS.
resultsWe analyzed 551 patients (587 breasts with cancer), including 61 carriers (64 breasts with cancer). During the median follow-up period of 5.3 years, the 5-year IBTR rates were 3.6% in the BRCA+ group and 5.1% in the BRCA- group, and the 10-year IBTR rates were 9.5% and 8.8%, respectively (p = 0.489). The median times to IBTR were 10.2 years in BRCA + and 3.5 years in BRCA-. The discordance rate of cancer subtypes between IBTR and primary cancer was significantly higher in BRCA+ than in BRCA- (p = 0.012). No significant differences were observed in the OS, BCSS, or DRFS between the two cohorts.
conclusionNo significant differences were observed in the IBTR risk or prognostic outcomes between BRCA + and BRCA- after BCS. However, the longer time to IBTR and the clinicopathological features potentially consistent with new primary cancers in BRCA+ suggest the importance of shared decision-making regarding BCS and long-term intensive breast surveillance after BCS in BRCA+.
Indexed as
Identifiers
42133182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.